Electromed, Inc. (NYSE:ELMD – Get Free Report) CFO Bradley Nagel sold 11,801 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $36.35, for a total value of $428,966.35. Following the completion of the sale, the chief financial officer directly owned 19,638 shares in the company, valued at $713,841.30. The trade was a 37.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Electromed Price Performance
NYSE ELMD opened at $37.18 on Thursday. The stock has a market capitalization of $307.85 million, a PE ratio of 49.57 and a beta of 0.53. Electromed, Inc. has a 1 year low of $17.73 and a 1 year high of $40.00. The business’s 50-day moving average is $30.28 and its 200 day moving average is $28.03.
Institutional Trading of Electromed
Hedge funds have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC boosted its position in shares of Electromed by 717.0% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 106,005 shares of the company’s stock worth $3,087,000 after purchasing an additional 93,030 shares in the last quarter. Hsbc Holdings PLC bought a new stake in shares of Electromed in the 4th quarter worth approximately $358,000. Hunter Associates Investment Management LLC boosted its position in shares of Electromed by 25.1% in the 1st quarter. Hunter Associates Investment Management LLC now owns 150,800 shares of the company’s stock worth $3,529,000 after purchasing an additional 30,250 shares in the last quarter. North Star Investment Management Corp. bought a new stake in shares of Electromed in the 1st quarter worth approximately $796,000. Finally, Punch & Associates Investment Management Inc. boosted its position in shares of Electromed by 6.6% in the 4th quarter. Punch & Associates Investment Management Inc. now owns 187,020 shares of the company’s stock worth $5,446,000 after purchasing an additional 11,500 shares in the last quarter. 40.82% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Read Our Latest Stock Analysis on ELMD
Electromed Company Profile
Electromed Inc (NYSE: ELMD) develops and manufactures sleep therapy products designed to support individuals with breathing disorders such as obstructive sleep apnea. The company’s core business activities include the design, production and distribution of continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP) accessories. Electromed’s focus on supplying both disposable and reusable components allows durable medical equipment providers to offer comprehensive therapy solutions to patients.
The company’s product portfolio encompasses masks, mask cushions, headgear, tubing, filters and humidification components.
Featured Stories
- Five stocks we like better than Electromed
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Electromed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electromed and related companies with MarketBeat.com's FREE daily email newsletter.
